Varying efficacy of intermittent preventive treatment for malaria in infants in two similar trials: public health implications by Menendez, Clara et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
Malaria Journal
Open Access Research
Varying efficacy of intermittent preventive treatment for malaria in 
infants in two similar trials: public health implications
Clara Menendez*1,2, David Schellenberg1,5,8, Eusebio Macete2,3, 
Pedro Aide2,4, Elizeus Kahigwa5,7, Sergi Sanz1, John J Aponte1,2, 
Jahit Sacarlal2, Hassan Mshinda5, Marcel Tanner6 and Pedro L Alonso1,2
Address: 1Barcelona Center for International Health Research (CRESIB), Hospital Clinic, Institut d'Investigacions Biomedicas August Pi i Sunyer 
(IDIBAPS), Universitat de Barcelona, Spain, 2Manhiça Health Research Center, Manhiça (CISM), Mozambique, 3National Directorate of Health, 
Maputo, Mozambique, 4National Institute of Health, Mozambique, 5Ifakara Health Research and Development Centre, Ifakara, Tanzania, 6Swiss 
Tropical Institute, Basel, Switzerland, 7World Health Organisation- Country Office, Dar es Salaam, Tanzania and 8London School of Hygiene and 
Tropical Medicine, (LSHTM), UK
Email: Clara Menendez* - menendez@clinic.ub.es; David Schellenberg - DMSchellenberg@aol.com; 
Eusebio Macete - eusebiomacete@yahoo.com; Pedro Aide - pedro.aide@manhica.net; Elizeus Kahigwa - ekahigwa@yahoo.com; 
Sergi Sanz - ssanz@clinic.ub.es; John J Aponte - jjairo@clinic.ub.es; Jahit Sacarlal - jahityash2002@yahoo.com.br; 
Hassan Mshinda - mshinda_hassan@yahoo.co.uk; Marcel Tanner - marcel.tanner@unibas.ch; Pedro L Alonso - palonso@clinic.ub.es
* Corresponding author    
Abstract
Background: Intermittent preventive treatment (IPTi) with sulphadoxine-pyrimethamine (SP) in
infants resulted in different estimates of clinical malaria protection in two trials that used the same
protocol in Ifakara, Tanzania, and Manhiça, Mozambique. Understanding the reasons for the
discrepant results will help to elucidate the action mechanism of this intervention, which is essential
for rational policy formulation.
Methods: A comparative analysis of two IPTi trials that used the same study design, follow-up,
intervention, procedures and assessment of outcomes, in Tanzania and Mozambique was
undertaken. Children were randomised to receive either SP or placebo administered 3 times
alongside routine vaccinations delivered through the Expanded Program on Immunisation (EPI).
Characteristics of the two areas and efficacy on clinical malaria after each dose were compared.
Results: The most relevant difference was in ITN's use ; 68% in Ifakara and zero in Manhiça. In
Ifakara, IPTi was associated with a 53% (95% CI 14.0; 74.1) reduction in the risk of clinical malaria
between the second and the third dose; during the same period there was no significant effect in
Manhiça. Similarly, protection against malaria episodes was maintained in Ifakara during 6 months
after dose 3, but no effect of IPTi was observed in Manhiça.
Conclusion: The high ITN coverage in Ifakara is the most likely explanation for the difference in
IPTi efficacy on clinical malaria. Combination of IPTi and ITNs may be the most cost-effective tool
for malaria control currently available, and needs to be explored in current and future studies.
Trial Registration: Manhiça study registration number: NCT00209795
Ifakara study registration number: NCT88523834
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Introduction
Despite increased attention to malaria control by donors,
researchers, clinicians, and communities, malaria contin-
ues to exact an intolerable toll, particularly in sub-Saharan
Africa. The development of new tools such as combina-
tion of drug therapies and insecticide treated nets (ITNs)
have offered hope, but their impact has been limited by
low implementation and logistical and financial con-
straints. No single tool currently exists that can drastically
reduce the malaria burden. Given this reality, and while
awaiting new technologies, the malaria community must
reexamine available data and interventions to look for cre-
ative and synergistic control strategies.
It is well documented and accepted that the burden of
malaria falls greatly on young children and infants [1].
Even in low/moderate malaria transmission settings,
where older children suffer the most malaria episodes,
infants have the highest fatality rate [2]. Finding cost-
effective and affordable approaches to deliver malaria
control interventions to infants is a public heath priority,
especially since adequate control may be followed by
important reductions in mortality for infants as well as
young children [3]. The Expanded Program on Immuniza-
tion (EPI) is the only available scheme that involves regu-
lar contact between the population at risk and the health
system, even in places with very limited access to services.
The intermittent preventive treatment in infants (IPTi)
consists of administering a treatment dose of an antima-
larial drug at predetermined intervals regardless of the
presence of parasitaemia or symptoms. Through the EPI,
it has the potential to become a cost-effective strategy.
IPTi with sulphadoxine-pyrimethamine (SP) has been
shown to significantly reduce malaria episodes in rand-
omized trials carried out in Tanzania, and more recently
in Ghana and Mozambique [4-6]. The effect of one treat-
ment dose of SP can last as long as 60 days [7]. Thus, the
administration of SP coinciding with immunizations
through the EPI scheme could provide a period of sup-
pressive prophylaxis that retains some beneficial effects of
regular chemoprophylaxis without compromising the
development of malaria immunity [8].
Despite the positive results for efficacy and safety, the
determinants and underlying protection mechanisms of
IPTi are not yet clear. The analysis of differences between
clinical trials that use similar designs could provide
insight into the potential determinants and possible
underlying protection mechanisms, as well as facilitate
planning for future policy recommendations. We had the
unique opportunity to compare two very similar IPTi tri-
als in two malaria endemic countries in Eastern and
Southern Africa. We present results from a comparative
analysis of the protective efficacy of IPTi, and examine the
factors that may explain the different protection levels
achieved [4,6]. The goal is that this information will help
garner future research and guide decision making about
the most appropriate role of IPTI in malaria control.
Methods
Study area and population
The Tanzanian study was based in Ifakara town, Kilomb-
ero District, in rural Tanzania and is described in detail
elsewhere [9]. Malaria transmission is perennial with two
rainy seasons and a cool, dry season from July to Septem-
ber. Plasmodium falciparum malaria transmission has been
intense in the area. The estimated mean annual entomo-
logical inoculation rate (EIR) was 300 bites/person/year
in the late 1980's and early 1990's in villages surrounding
Ifakara town [10]. However, in the last years, malaria
transmission in the semi-urban area of Ifakara decreased
[2,9] to an overall EIR of 29 infective bites per person per
year [11]. Anopheles gambiae, and to a lesser extent Anoph-
eles funestus, are the main vectors. The Ifakara population
was estimated to be 55.000 people.
In Ifakara, SP was not associated with any late treatment
failures, had a in vivo parasitological sensitivity of 69% at
day 14 [12], and was the nationally recommended first
line treatment for malaria during the study duration.
Compliance to routine EPI vaccinations was high; 92% of
children received three doses of DTP/OPV and 80%
received measles. HIV seroprevalence at antenatal visits
was 6.7% in 1998 [13], The use of insecticide treated nets
(ITNs) was about 70%. The prevalence of haemoglobin
AS genotype in the study children was 12% [4].
In Mozambique the trial was conducted in Manhiça town,
Manhiça District, in southern Mozambique. The charac-
teristics of the area have been described in detail else-
where [14]. The climate is subtropical with a warm and
rainy season from November to April, and a cool and dry
season during the rest of the year. Perennial malaria trans-
mission with marked seasonality is mostly due to P. falci-
parum. Anopheles funestus is the main vector and the EIR for
2002 was 38. The population under demographic surveil-
lance was about 70.000 people.
During the Mozambique study, first line treatment of
uncomplicated malaria changed from chloroquine to
amodiaquine plus SP Most recent data from 2001 on the
efficacy of SP in this area showed a combined therapeutic
efficacy rate of 83% of children treated, with an in vivo par-
asitological sensitivity of 78.6% at day 14 [15]. Compli-
ance with EPI vaccines was very high, more than 95% of
children received all three doses of DTP/polio/Hepatitis B
and more than 85% received measles. HIV seroprevalence
in antenatal women was 19% in 2003, (Berenguera et al
submitted) and ITN use was zero; only 15% of childrenMalaria Journal 2007, 6:132 http://www.malariajournal.com/content/6/1/132
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used non-treated nets [6]. No individuals homozygous for
sickle cell or carriers have been found in the area through
community and hospital based surveys (Menendez
unpublished data).
Study design
Detailed descriptions of the Ifakara [4] and Manhica trials
are provided elsewhere [6]. Briefly, in Ifakara infants were
recruited at the MCH clinic immediately after receiving
dose 2 of DTP/OPV between August 1999 and April 2000.
IPTi was given at ages 2, 3, and 9 months alongside rou-
tine EPI vaccinations (Figure 1a). In Manhiça, children
were recruited from those attending the EPI clinic to
receive dose 2 of DTP/OPV/Hep B between September
2002 and February 2004 (Figure 1b). Identical randomi-
zation, blinding, treatment concealment and allocation
procedures and inclusion and exclusion criteria were fol-
lowed in each study. Tablets of SP and placebo (consisting
of lactose and maize starch) were identical in shape and
color and stored in bottles labeled only with a single treat-
ment identification letter by investigators not involved in
the studies. Placebo and SP tablets were provided by the
same manufacturer (Hoffman La Roche, Basel, Switzer-
land). Doses of SP/placebo were administered by a health
assistant according to body weight (< 5 kg-1/4 tablet, 5–
10 kg-1/2 tablet, > 10 kg-1 tablet), crushed and mixed
with water on a tablespoon.
Follow-up
Assessment of outcomes was similar in both studies.
Comparable round-the-clock hospital-based clinical sur-
veillance systems were operating in both sites; at each con-
sultation a detailed standardized questionnaire was
completed to document signs and symptoms [16,17].
Blood films were prepared for malaria parasite examina-
tion, and the packed cell volume (PCV) was measured if
there was a history of fever in the preceding 24 hrs, the
axillary temperature was ≥ 37.5°C or the child appeared
pale. In Ifakara a previous study showed that prophylactic
iron supplements had a significant impact in reducing
severe anemia without increasing the risk of malaria [8].
Therefore, iron supplements were dispensed to all chil-
dren for 4 months (from 2–6 months of age). Iron supple-
ments were not given as part of the Manhiça trial.
Laboratory methods
Thick and thin blood films were stained and read accord-
ing to standard, quality-controlled procedures [19]. The
packed cell volume (PCV) was measured in a microcapil-
lary tube after centrifugation.
Efficacy assessment
The impact of IPTi with SP on malaria morbidity was
assessed through passive clinical surveillance and cross-
sectional surveys carried out at ages12 and 18 months in
Ifakara, and at ages 12 and 24 months in Manhiça.
Effects of IPTi
In the Ifakara study, first or only episodes of clinical
malaria were reduced by 59% (95% CI, 41; 72%), and the
incidence of severe anemia dropped by 50% (95% CI, 8;
73%) [4]. After the intervention was discontinued, a pro-
tective effect of 36% (95% CI, 11; 53%) in the incidence
of clinical malaria episodes was observed during the
extended follow-up that covered the time at-risk starting 1
month after dose 3 of IPTi until age 2 years [18]. In Man-
hiça, first or only episodes of clinical malaria were
reduced by 22.2% (95% CI, 3.7; 37.0; p = 0.020) The inci-
dence of severe anemia up to age 1 year did not differ sig-
nificantly between the SP and placebo groups [12.7%
(95% CI, -17.3; 35.1%), p = 0.36]. The incidence of clini-
cal malaria did not differ between the two intervention
arms after discontinuation of IPTi during the extended
follow-up. At both sites IPTi was associated with a signifi-
cant reduction in risk of admission to hospital [Ifakara
28% (95% CI, 7; 45%), Manhiça 19% (95% CI, 4; 31%)].
Statistical methods and definitions
The original data was re-analyzed at individual level using
more stringent criteria than originally to include children
in both cohorts that: i) received three doses of IPTi; ii)
received the last IPTi dose between 9 and 10 months of
age; and iii) had at least 1 month of follow-up after the
last IPTi dose. Five periods were defined: i) 1 month after
IPTi dose 1; ii) 1 month after IPTi dose 2; iii) 1 month
after dose 2 until dose 3; iv) 1 month after dose 3; and v)
6 months, starting 1 month after dose 3.
Clinical malaria was defined as fever (axillary temperature
≥ 37.5°C) plus a Plasmodium falciparum asexual parasitae-
mia. Cox regression models were used to compare the
hazards for the time to first or only episode of clinical
malaria in each period. The interaction between study and
treatment effect was evaluated using the likelihood ratio
test.
Results
Main characteristics of both trials are summarized in
Table 1. The most striking difference between the two sites
is ITN use. In Ifakara, a successful social marketing scheme
promoting ITN use resulted in a 68% ITN coverage [20].
At the time of the trial, the use of ITNs was zero in Man-
hiça. The HIV seroprevalence was higher in Manhiça
(19%) than in Ifakara (6.7%). SP efficacy was similar in
the two sites.
The analysis estimated the protective efficacy of SP for 30
days after each IPTi dose and found protection above 50%
in both sites (Table 2). The analysis also estimated the riskMalaria Journal 2007, 6:132 http://www.malariajournal.com/content/6/1/132
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a.Individual timeline Ifakara Figure 1
a. Individual timeline Ifakara. b. Individual timeline Manhiça.
Figure 1a. Individual timeline Ifakara
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of malaria for the periods when there should have been
no pharmacological effect the period between the second
and the third IPTi doses and the 6 months beginning 30
days after the third dose (Table 2). The results show that
SP efficacy was lower in Manhiça compared to Ifakara
between the second and third doses [14.7% (95% CI, -
14.6; 36.5) vs 52% (95% CI, 14.0; 74.1)] and for the
period after the third dose [7.4 (95%, CI -21; 29.3) vs
32.2% (95% CI, -3.5; 55.6)].
Discussion
Intermittent preventive treatment with SP had different
protective efficacies in reducing malaria and anemia inci-
dence in these two malaria endemic settings in sub-Saha-
ran Africa. The two trials were very similar in most aspects.
Randomization, intervention, follow-up and assessment
of outcome procedures were close to identical. The active
drug and placebo were manufactured by the same phar-
maceutical company. Intensity of malaria transmission
during the course of both studies was comparable, not
only in the comparable EIR, but also in the rates of
malaria episodes in the placebo groups during the first
year of life (Table 1). At the time of the trials, parasitolog-
ical resistance and clinical response to SP were similar,
and information obtained shortly before the trials started
showed that the drug had an adequate level of efficacy in
both settings [12-15]. Moreover, the analysis during the
month after each dose (Table 2) shows that SP efficacy
was above 50% in both sites. Therefore, it is unlikely that
a reduced parasitological efficacy of SP in Manhiça could
solely account for the observed difference in clinical pro-
tection.
The overall incidence of severe anaemia up to 1 year of age
was not significantly affected by the SP intervention in
Manhiça [6]. Prophylactic iron supplements were not
given to study infants in the Mozambican study since this
is not part of the standard of care. In Ifakara, on the other
hand, prophylactic ferrous sulphate was given for 4
months to all study participants. The discrepancy in ane-
mia prevention between the two trials could be because
malaria is less important than other causes of anaemia in
infants in the Manhiça area. An alternative explanation is
that protection against malaria needs to be sustained to
have a significant impact on associated anaemia. This
would also explain the significant effect of IPTi on anae-
mia in Ifakara where the intervention was given in the
context of high ITN's coverage. Moreover, another study
in this same setting found a significant reduction in the
risk of anaemia in infancy by weekly malaria chemo-
prophylaxis for 10 months [8].
The administration of the IPTi regimen differed slightly in
the two trials because of the different EPI immunization
schedules. Consequently, in Ifakara the first two doses
were given at 2 and 3 months, while in Manhiça they were
administered at 3 and 4 months of age. It is unlikely that
this variation in the intervention regimen would explain
the difference found in the efficacy; particularly since the
time between administration of the second and third dose
was shorter in Mozambique. The risk of malaria is greater
between age 5 and 9 months than during the first 3
months of life, and thus implies a theoretical advantage to
the infants in the Manhiça study, which was not observed
[21].
Table 1: Main characteristics of the area and intervention in Ifakara and Manhiça
Ifakara Manhiça
Years of intervention 1999–2001 2002–2004
Number of children randomized 701 1503
Incidence of malaria in placebo groupa 0.36 0.43
EIR* 29 38
Transmission Perennial Perennial with marked seasonality
IPTi regimen** 2, 3, 9 3, 4, 9
Iron supplementation** 2–6 -
1st line Malaria Treatment during study SP SP + AQ
ITN use 68% 0
HIV seroprevalence (at ANC) 6.7% 19%
Hb AS prevalence *** 12% 0
SP parasitological sensitivity# 69% (62/90) 78.6% (55/70)
SP ACR# 94% (84/89) 83% (67/81)
*EIR = Entomological inoculation rate
**months of age
*** hemoglobin AS genotype
# at day 14. ACR = adequate clinical response
a episode/child/yearMalaria Journal 2007, 6:132 http://www.malariajournal.com/content/6/1/132
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HIV infection during pregnancy has been associated with
increased susceptibility to malaria and lower efficacy of
IPT with SP [22]. In contrast, no information exists on the
impact of the co-infection in children [23]. The HIV infec-
tion status was not recorded for children participating in
either trial. However, HIV seroprevalence at antenatal
clinics differed between the two sites, and it is expected
that slightly more enrolled infants in Manhiça would have
been infected than in Ifakara. Although specific studies are
needed to look at this interaction in children, it is unlikely
that HIV associated immunosuppression played an
important role in reducing the impact of the intervention
in the Manhiça study at the magnitude observed.
The analysis presented in this paper shows that, as
expected, the risk of malaria was greatly reduced for 1
month in children who received a stat dose of a moder-
ately effective antimalarial. However, the different protec-
tion levels between the two trials is mainly explained by
the difference in risk of malaria outside the window of
time when the drug is efficacious. There are no obvious
reasons that explain these findings. In a previous report
we have hypothesized that this reduced risk is a function
of the accelerated acquisition of immunity in children
receiving IPTi in the first year of life [18]. The question
arises why this accelerated acquisition of immunity did
not occur in Manhiça. The only remarkable difference
between the two sites that could explain this difference
refers to the wide-scale use of ITNs in Ifakara. It points to
a possible synergistic effect between IPTi and ITNs that
reduces the dose of infection from the mosquito and
allows an improved acquisition of immunity. This would
explain why there is no rebound effect after stopping IPTi
in Ifakara, and there is even a sustained reduction of the
risk of clinical malaria extending beyond the pharmaco-
logical effect of the drug [18]. This additive protection of
drugs and ITNs is supported by the results of a study in
The Gambia, where the combination of weekly chemo-
prophylaxis and ITNs provided substantial additional
protection against malaria infection and clinical malaria
attacks [3].
Conclusion
This comparative analysis provides an example of how
existing data sources can be used to fine-tune malaria con-
trol strategies in the immediate future. Contrary to earlier
speculation [24], the results suggest that, ITNs and IPTi
may act synergistically. Combining these two cost-effec-
tive interventions may enhance malaria control, and
therefore policy makers considering IPTi as an strategy
should include provisions for the sustained use of ITNs.
This effect, although encouraging, should be further eval-
uated in current IPTi trials and future studies, before it can
be considered conclusive. Finally, this analysis reiterates
the need to carry out careful evaluation of malaria control
measures in varied settings before widespread recommen-
dations are made.
Table 2: SP effect on the incidence of clinical malaria during different periods in Ifakara and Manhiça
Outcome Placebo SP* Protective efficacy p
Events PYAR Rate Events PYAR Rate (95% CI)
During 1 month after dose 1
Ifakara 8 21.71 0.37 1 22.21 0.05 87.8% (2.3;98.5) 0.012
Manhiça 13 47.48 0.27 1 49.97 0.02 92.7% (44.2;99.0) < 0.001
Combined effect adjusted by study 21 69.19 0.30 2 72.18 0.03 90.9% (61.0;97.9) < 0.001
During 1 month after dose 2 
Ifakara 6 21.83 0.27 0 22.41 0.00 100% (.;100) 0.004
Manhiça 23 47.33 0.49 10 50.27 0.20 59.0% (13.8;80.5) 0.014
From 1 month after dose 2 until dose 3
Ifakara 32 100.08 0.32 16 106.04 0.15 52.8% (14.0;74.1) 0.011
Manhiça 92 169.09 0.54 85 183.36 0.46 14.7% (-14.6;36.5) 0.292
During 1 month after dose 3
Ifakara 14 21.51 0.65 2 22.32 0.09 86.2% (39.4;96.9) 0.001
Manhiça 32 46.94 0.68 16 49.82 0.32 52.7% (13.9;74.1) 0.012
During 6 months from 1 month after dose 3
Ifakara 51 112.56 0.45 37 120.90 0.31 32.2% (-3.5;55.6) 0.070
Manhiça 107 228.31 0.47 104 239.31 0.43 7.4% (-21.3;29.3) 0.578
*Sulphadoxine-pyrimethamineMalaria Journal 2007, 6:132 http://www.malariajournal.com/content/6/1/132
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